A research based on data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) demonstrated that the reporting OR (ROR) (95% CI) for heart failure and QTc prolongation in comparing osimertinib vs. other EGFR-TKIs was 2.2 (1.5–3.2) and 6.6 (3.4–12.8) (3). This evidence concerns the gene EGFR and heart failure.